Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
Status:
Completed
Trial end date:
2000-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of irinotecan plus carmustine in treating
patients who have recurrent primary malignant glioma.